Country: United States
Language: English
Source: NLM (National Library of Medicine)
GADOBUTROL (UNII: 1BJ477IO2L) (GADOLINIUM CATION (3+) - UNII:AZV954TZ9N)
Slate Run Pharmaceuticals, LLC
INTRAVENOUS
PRESCRIPTION DRUG
Gadobutrol injection is indicated for use with magnetic resonance imaging (MRI) in adult and pediatric patients, including term neonates to detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system. Gadobutrol injection is indicated for use with MRI in adult patients to assess the presence and extent of malignant breast disease. Gadobutrol injection is indicated for use in magnetic resonance angiography (MRA) in adult and pediatric patients, including term neonates, to evaluate known or suspected supra-aortic or renal artery disease. Gadobutrol injection is indicated for use in cardiac MRI (CMRI) to assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD). Gadobutrol injection is contraindicated in patients with history of severe hypersensitivity reactions to gadobutrol injection. GBCAs cross the placenta and result in fetal exposure and gadolinium retention.
Gadobutrol injection is a sterile, clear and colorless to pale yellow solution containing 604.72 mg gadobutrol per mL (equivalent to 1 mmol gadobutrol) per mL. Gadobutrol injection is supplied in the following sizes: Single-Dose Containers (Vials) Store at 20° to 25°C (68° to 77°F); excursions permitted to 15° to 30°C (59° to 86°F). [See USP Controlled Room Temperature]. Should freezing occur, gadobutrol injection should be brought to room temperature before use. If allowed to stand at room temperature, gadobutrol injection should return to a clear and colorless to pale yellow solution. Visually inspect gadobutrol injection for particulate matter and discoloration prior to administration. Do not use the solution if it is discolored, if particulate matter is present or if the container appears damaged.
Abbreviated New Drug Application
GADOBUTROL- GADOBUTROL INJECTION Slate Run Pharmaceuticals, LLC ---------- MEDICATION GUIDE GADOBUTROL INJECTION Gadobutrol (gad” oh bue’ trol) Injection for intravenous use What is the most important information I should know about gadobutrol injection? • Gadobutrol injection contains a metal called gadolinium. Small amounts of gadolinium can stay in your body including the brain, bones, skin and other parts of your body for a long time (several months to years). • It is not known how gadolinium may affect you, but so far, studies have not found harmful effects in patients with normal kidneys. • Rarely, patients have reported pains, tiredness, and skin, muscle or bone ailments for a long time, but these symptoms have not been directly linked to gadolinium. • There are different GBCAs that can be used for your MRI exam. The amount of gadolinium that stays in the body is different for different gadolinium medicines. Gadolinium stays in the body more after Omniscan or Optimark than after Eovist, Magnevist, or MultiHance. Gadolinium stays in the body the least after Dotarem, gadobutrol injection, or ProHance. • People who get many doses of gadolinium medicines, women who are pregnant and young children may be at increased risk from gadolinium staying in the body. • Some people with kidney problems who get gadolinium medicines can develop a condition with severe thickening of the skin, muscles and other organs in the body (nephrogenic systemic fibrosis). Your healthcare provider should screen you to see how well your kidneys are working before you receive gadobutrol injection. What is gadobutrol injection? • Gadobutrol injection is a prescription medicine called a gadolinium-based contrast agent (GBCA). Gadobutrol injection, like other GBCAs, is injected into your vein and used with a magnetic resonance imaging (MRI) scanner. • An MRI exam with a GBCA, including gadobutrol injection, helps your doctor to see problems better than an MRI exam without a GBCA. • Your doctor has reviewed your medical Read the complete document
GADOBUTROL- GADOBUTROL INJECTION SLATE RUN PHARMACEUTICALS, LLC ---------- HIGHLIGHTS OF PRESCRIBING INFORMATION THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE GADOBUTROL INJECTION SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR GADOBUTROL INJECTION. GADOBUTROL INJECTION, FOR INTRAVENOUS USE INITIAL U.S. APPROVAL: 2011 WARNING: NEPHROGENIC SYSTEMIC FIBROSIS (NSF) _SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._ GADOLINIUM-BASED CONTRAST AGENTS (GBCAS) INCREASE THE RISK FOR NSF AMONG PATIENTS WITH IMPAIRED ELIMINATION OF THE DRUGS. AVOID USE OF GBCAS IN THESE PATIENTS UNLESS THE DIAGNOSTIC INFORMATION IS ESSENTIAL AND NOT AVAILABLE WITH NON-CONTRASTED MRI OR OTHER MODALITIES. THE RISK FOR NSF APPEARS HIGHEST AMONG PATIENTS WITH: 1. CHRONIC, SEVERE KIDNEY DISEASE (GFR <30 ML/MIN/1.73M ), OR 2. ACUTE KIDNEY INJURY. SCREEN PATIENTS FOR ACUTE KIDNEY INJURY AND OTHER CONDITIONS THAT MAY REDUCE RENAL FUNCTION. FOR PATIENTS AT RISK FOR CHRONICALLY REDUCED RENAL FUNCTION (FOR EXAMPLE, AGE >60 YEARS, HYPERTENSION OR DIABETES), ESTIMATE THE GLOMERULAR FILTRATION RATE (GFR) THROUGH LABORATORY TESTING. ( 5.1) INDICATIONS AND USAGE Gadobutrol injection is a gadolinium-based contrast agent indicated for use with magnetic resonance imaging (MRI): 1. To detect and visualize areas with disrupted blood brain barrier and/or abnormal vascularity of the central nervous system in adult and pediatric patients, including term neonates ( 1.1) 2. To assess the presence and extent of malignant breast disease in adult patients ( 1.2) 3. To evaluate known or suspected supra-aortic or renal artery disease in adult and pediatric patients, including term neonates ( 1.3) 4. To assess myocardial perfusion (stress, rest) and late gadolinium enhancement in adult patients with known or suspected coronary artery disease (CAD) ( 1.4) DOSAGE AND ADMINISTRATION Recommended dose for adults and pediatric patients (including term neonates) is 0.1 mL/kg body weight ( 2.1) Administer as an intravenous bolus inject Read the complete document